Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma

NCT05080790 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Leiomyosarcoma

Interventions

DRUG: Dinutuximab Beta, Zoledronic acid, Interleukin-2

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

[object Object]